« Faking Two Papers A Month. For Seven Years. |
| Sanofi Announces Layoffs »
November 2, 2011
Tiny, Tiny Molecules for MS
What is the deal with multiple sclerosis and small off-the-shelf molecules? Last year I wrote about Ampyra, which is 4-aminopyridine. Now Biogen is showing what looks like good results with BG-12, which is. . .dimethyl fumarate. See the Haystack blog for more. The same comments I made earlier about Ampyra's intellectual property situation apply here - it's just interesting to see that Biogen has a hand in both of these. What's next? Toluene?
+ TrackBacks (0) | Category: The Central Nervous System
POST A COMMENT
- RELATED ENTRIES
- How Not to Do It: NMR Magnets
- Allergan Escapes Valeant
- Vytorin Actually Works
- Fatalities at DuPont
- The New York TImes on Drug Discovery
- How Are Things at Princeton?
- Phage-Derived Catalysts
- Our Most Snorted-At Papers This Month. . .